Tagged with oncology,

China With proactive government support and an increasingly specialised workforce, China has become one of the leading nations in the development of Chimeric Antigen Receptor T-cell (CAR-T) therapies, along with the US. More than 200 CAR-T therapies are being developed in China, and the number of ongoing clinical trials continues to…

China Dr Laura Benjamin, CEO of Oncologie, shares the rationale behind their exceptional decision to simultaneously establish offices in both the US and China; their unique biomarker approach focusing on the individual patient’s tumor microenvironment; their strategy to differentiate their approaches to in-licensing as well as combination plays within the area…

Switzerland With cancer now causing one in eight deaths globally and, in Europe, even outpacing serious cardiovascular conditions in terms of prevalence, Switzerland has long positioned itself firmly at the vanguard of countering a disease which the World Health Organization (WHO) predicts will reach an incidence rate of 22 million new…

Oncology Cancer is on the rise in Hungary and survival rates are considerably lower than the European average. The country’s innovative pharma association has taken the initiative to suggest measures that it believes would drastically improve cancer mortality rates and quality of life for oncology patients.   Recent statistics show that…

Sweden Ascelia Pharma is a Swedish oncology start-up based in Malmö. CEO Magnus Corfitzen talks about the opportunities they have found in the orphan oncology drug market, the promising phase III study for their lead asset, Mangoral, and his journey navigating the Swedish life science industry.   With Mangoral, we are…

China The US FDA has granted orphan drug designation to Shanghai-headquartered biotech CARsgen Therapeutics’ CAR-T cell therapy CT053 for multiple myeloma after positive results were observed in the phase I trial efficacy evaluation.   19 of 24 patients with relapsed and refractory multiple myeloma showed complete response Zonghai Li, CARSgen Therapeutics…

China Dr. Chris Lu, CEO and cofounder of Laekna Therapeutics, shares Laekna’s ambition to deliver cures and improve the quality of life of patients globally, captured by the word ‘Laekna’, which is Old Norse for ‘to cure, to heal’. He also outlines Laekna’s focus on disease biology, specifically the areas of…

Thailand Dr Ekaphop Sirachainan, president of the Thai Society of Clinical Oncology, explains the need to increase patient access to oncology treatment in Thailand, and the crucial need for collaboration with the public sector in terms of prevention and to spread information to all healthcare professionals. Sirachainan also underlines the importance…

Europe Janssen’s EMEA market access head Martin Price outlines the regulatory changes that need to be made for patients across Europe to better access cutting-edge cancer medicines.   Recent advances in medical science are the driving force behind the research and successful development of innovative cancer treatments in Europe. By targeting…

Taiwan Dr Mien-Chie Hung, president of China Medical University, shares his personal mission upon taking the role only three months ago. Dr Hung also elaborates on the research strengths of CMU and goes on to give his view on what role Taiwan and the university can play in tackling the Asian…

Spain Stefanie Granado, director general of Takeda Iberia recounts the opportunities available for Takeda in Spain following its acquisition of Shire. She also discusses Takeda’s local acquisition of TiGenix, handing Takeda stem cell production capabilities, and how this makes Spain a key market and hub for the company.   We continue…

Taiwan Dr James Chih-Hsin Yang, director of National Taiwan University Hospital’s department of oncology, speaks about oncology in Taiwan and the role that the NTU network plays in the island’s oncology space. Dr Yang goes on to share his insights on key trends shaping modern and future cancer treatment.   We…